MRC SUPREMO (BIG 2-04) Selective Use of Postoperative Radiotherapy aftEr MastectOmy Phase III randomised trial of chest wall RT in intermediate- risk breast.
Should clinicians routinely recommend trastuzumab (Herceptin) as part of the adjuvant therapy for all patients with Her2 positive early breast cancer?
MRC SUPREMO (BIG 2-04) S elective U se of P ostoperative R adiotherapy aft E r M astect O my
